Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

901
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
901
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

742
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
742
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

399
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
399
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

544
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
544
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

676
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
676
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

851
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
851

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biochemical profiling and symptomatology of androgen deficiency in males with cluster headache: A prospective case-control study.

Headache·2026
Same author

Tsunamis hiding in plain sight: spreading depression in clinical neurology.

Nature reviews. Neurology·2026
Same author

2025 Highlights in cluster headache.

Cephalalgia : an international journal of headache·2026
Same author

Risk and reward seeking behaviour in episodic cluster headache - a psychometric and behavioural study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Is it time to think about chronotherapy in migraine.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025
Same author

Cannabis Use in Central Disorders of Hypersomnolence in the Netherlands.

Medical cannabis and cannabinoids·2025
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
09:35

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain

Published on: May 10, 2017

19.3K

Pharmacotherapy for Cluster Headache.

Roemer B Brandt1,2, Patty G G Doesborg3, Joost Haan3,4

  • 1Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. r.b.brandt@lumc.nl.

CNS Drugs
|January 31, 2020
PubMed
Summary
This summary is machine-generated.

Cluster headache involves severe facial pain with autonomic symptoms. Treatment includes fast-acting options like sumatriptan and oxygen, alongside preventive medications such as verapamil and lithium.

More Related Videos

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.6K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.2K

Related Experiment Videos

Last Updated: Dec 29, 2025

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
09:35

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain

Published on: May 10, 2017

19.3K
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.6K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.2K

Area of Science:

  • Neurology
  • Pain Medicine

Background:

  • Cluster headache is a severe neurological disorder characterized by excruciating unilateral head or facial pain.
  • Attacks are accompanied by ipsilateral autonomic symptoms, including ptosis, miosis, facial flushing, nasal congestion, and restlessness.

Purpose of the Study:

  • To review current treatment strategies for cluster headache.
  • To discuss abortive, transitional, and preventive treatment options.

Main Methods:

  • Literature review of established and emerging cluster headache treatments.
  • Analysis of evidence for various pharmacological and neuromodulatory interventions.

Main Results:

  • Subcutaneous sumatriptan and high-flow oxygen are effective abortive treatments.
  • Verapamil and lithium are first-line preventive drugs, with ECG and liver/kidney function monitoring recommended.
  • Topiramate is a second-line option, and other treatments like galcanezumab are emerging.
  • Greater occipital nerve injection is a proven transitional treatment.

Conclusions:

  • Effective management of cluster headache requires a multi-modal approach including abortive, transitional, and preventive therapies.
  • Individualized treatment selection is crucial, considering efficacy, side effects, and patient-specific factors.
  • Further research is needed for long-term effects of newer treatments like galcanezumab.